干细胞治疗终末期肝病的进展

Progress of the application of stem cell therapy for end-stage liver disease

许多致病因素都能导致肝功能极度减退甚至衰竭,从而进入终末期肝病阶段,常规治疗手段对于终末期肝病的疗效始终不理想。原位肝移植虽较为有效,但是因为费用高、肝源不足、免疫排斥等因素,不能大规模应用于临床,细胞治疗一直为临床所期待。肝疾病细胞治疗细胞来源以及利用胚胎干细胞和人诱导性多能干细胞向肝细胞诱导的研究近年来有了长足进展。随着干细胞技术的兴起与发展以及诱导技术的逐步成熟,解决了肝细胞来源稀缺的问题,为治疗终末期肝病提供了新的思路。

Many risk factors lead to hypohepatia and hepatic failure, causing people suffering from end-stage liver disease. The conventional treatment for end-stage liver disease is not good enough. Orthotopic liver transplantation is effective. However, the high cost, lack of liver source, immune rejection and other factors limit the large-scale clinical application. Thus, cell therapy is a good option. Studies on common cell sources for the treatment of liver disease and the induction of hepatocytes by embryonic stem cells or pluripotent stem cells have made progress. With the development of stem cell technology, cell transplantation has become a new option, which brings hope to people with end-stage liver diseasetransplantation has become a new option. It brings hope to people with end- stage liver disease.